Literature DB >> 22751346

Cancer: thyroid cancer bone metastases and high morbidity rates.

Ann Gramza, Electron Kebebew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22751346      PMCID： PMC6959530          DOI： 10.1038/nrendo.2012.112

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

2.  Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.

Authors:  Yorihisa Orita; Iwao Sugitani; Kazuhisa Toda; Jun Manabe; Yoshihide Fujimoto
Journal:  Thyroid       Date:  2010-11-08       Impact factor: 6.568

3.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Predictors of skeletal complications in patients with metastatic breast carcinoma.

Authors:  S M Domchek; J Younger; D M Finkelstein; M V Seiden
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

5.  Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival.

Authors:  Hadiza S Kazaure; Sanziana A Roman; Julie A Sosa
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

6.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

Review 7.  Bisphosphonates: clinical experience.

Authors:  Robert E Coleman
Journal:  Oncologist       Date:  2004

Review 8.  Bone metastases from differentiated thyroid carcinoma.

Authors:  M M Muresan; P Olivier; J Leclère; F Sirveaux; L Brunaud; M Klein; R Zarnegar; G Weryha
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

9.  Skeletal-related events due to bone metastases from differentiated thyroid cancer.

Authors:  Azeez Farooki; Vivien Leung; Hernan Tala; R Michael Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2012-05-07       Impact factor: 5.958
  9 in total
  2 in total

1.  The impact of complete surgical resection of spinal metastases on the survival of patients with thyroid cancer.

Authors:  Satoshi Kato; Hideki Murakami; Satoru Demura; Yoshiyasu Fujimaki; Katsuhito Yoshioka; Noriaki Yokogawa; Hiroyuki Tsuchiya
Journal:  Cancer Med       Date:  2016-07-19       Impact factor: 4.452

2.  Locoregional progression-free survival of bone metastases from differentiated thyroid cancer.

Authors:  Jiaxin Luo; Weili Yin; Qiuxia Lin; Juqing Wu; Pan Chen; Yuanna Ling; Jing Wang; Zhen Li; Liqin Pan; Yanying Chen; Wei Ouyang; Huijuan Feng
Journal:  Endocr Connect       Date:  2022-03-24       Impact factor: 3.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.